Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22152235 | 0.84 | MAPK1 (0.35) | MAPK1NPSR1KDM4EMAPTTHRB | |
| SCHEMBL28657275 | 0.84 | MAPK1 (0.35) | MAPK1NPSR1KDM4EMAPTTHRB | |
| SCHEMBL26097774 | 0.83 | MAPK1 (0.36) | MAPK1NPSR1KDM4EMAPTTHRB | |
| SCHEMBL8240722 | 0.80 | NPSR1 (0.33) | HSD17B10NPSR1 | |
| SCHEMBL10299133 | 0.80 | NPSR1 (0.33) | HSD17B10NPSR1 | |
| SCHEMBL628012 | 0.80 | NPSR1 (0.33) | HSD17B10NPSR1 | |
| SCHEMBL3731484 | 0.80 | NPSR1 (0.33) | HSD17B10NPSR1 | |
| SCHEMBL10298837 | 0.78 | NPSR1 (0.32) | HSD17B10NPSR1 | |
| SCHEMBL2433549 | 0.77 | MAPK1 (0.36) | MAPK1NPSR1MAPT | |
| SCHEMBL2435499 | 0.75 | CRBN (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | MAPK1 3015/4885HSD17B10 594/4885NPSR1 3014/4885 |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | MAPK1 3507/4885HSD17B10 913/4885NPSR1 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.